193 related articles for article (PubMed ID: 36517738)
21. Prevalence of anti-aquaporin 4 antibody in a diagnostic cohort of patients being investigated for possible neuromyelitis optica spectrum disorder in Western Australia.
Fabis-Pedrini MJ; Bundell C; Wee CK; Lucas M; McLean-Tooke A; Mastaglia FL; Carroll WM; Kermode AG
J Neuroimmunol; 2018 Nov; 324():76-80. PubMed ID: 30248527
[TBL] [Abstract][Full Text] [Related]
22. Impact of comorbid Sjögren syndrome in anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders.
Akaishi T; Takahashi T; Fujihara K; Misu T; Fujimori J; Takai Y; Nishiyama S; Abe M; Ishii T; Aoki M; Nakashima I
J Neurol; 2021 May; 268(5):1938-1944. PubMed ID: 33416998
[TBL] [Abstract][Full Text] [Related]
23. Anti-aquaporin-1 autoantibodies in patients with neuromyelitis optica spectrum disorders.
Tzartos JS; Stergiou C; Kilidireas K; Zisimopoulou P; Thomaidis T; Tzartos SJ
PLoS One; 2013; 8(9):e74773. PubMed ID: 24086369
[TBL] [Abstract][Full Text] [Related]
24. Memantine ameliorates motor impairments and pathologies in a mouse model of neuromyelitis optica spectrum disorders.
Yick LW; Tang CH; Ma OK; Kwan JS; Chan KH
J Neuroinflammation; 2020 Aug; 17(1):236. PubMed ID: 32782018
[TBL] [Abstract][Full Text] [Related]
25. Optic neuritis in neuromyelitis optica.
Levin MH; Bennett JL; Verkman AS
Prog Retin Eye Res; 2013 Sep; 36():159-71. PubMed ID: 23545439
[TBL] [Abstract][Full Text] [Related]
26. A comprehensive review of the advances in neuromyelitis optica spectrum disorder.
Siriratnam P; Huda S; Butzkueven H; van der Walt A; Jokubaitis V; Monif M
Autoimmun Rev; 2023 Dec; 22(12):103465. PubMed ID: 37852514
[TBL] [Abstract][Full Text] [Related]
27. Comparative study of AQP4-NMOSD, MOGAD and seronegative NMOSD: a single-center Belgian cohort.
Dauby S; Dive D; Lutteri L; Andris C; Hansen I; Maquet P; Lommers E
Acta Neurol Belg; 2022 Feb; 122(1):135-144. PubMed ID: 34097296
[TBL] [Abstract][Full Text] [Related]
28. Asymptomatic MRI lesions in pediatric-onset AQP4-IgG positive NMOSD.
Paolilo RB; Rimkus CM; da Paz JA; Apostolos-Pereira SL; Callegaro D; Sato DK
Mult Scler Relat Disord; 2022 Dec; 68():104215. PubMed ID: 36257150
[TBL] [Abstract][Full Text] [Related]
29. Seronegative Neuromyelitis Optica Spectrum--the challenges on disease definition and pathogenesis.
Sato DK; Callegaro D; Lana-Peixoto MA; Nakashima I; Fujihara K
Arq Neuropsiquiatr; 2014 Jun; 72(6):445-50. PubMed ID: 24964112
[TBL] [Abstract][Full Text] [Related]
30. Utility of aquaporin-4 antibody assay in patients with neuromyelitis optica spectrum disorders.
Kim SM; Waters P; Woodhall M; Kim JY; Kim JE; Yang JW; Kim JS; Sung JJ; Park KS; Lee KW
Mult Scler; 2013 Jul; 19(8):1060-7. PubMed ID: 23329699
[TBL] [Abstract][Full Text] [Related]
31. Aquaporin-4-antibody-positive Neuromyelitis Optica Spectrum Disorder in a Patient with Charcot-Marie-Tooth Disease Type 1A.
Hamada Y; Takahashi K; Kanbayashi T; Hatanaka Y; Kobayashi S; Sonoo M
Intern Med; 2021 May; 60(10):1611-1614. PubMed ID: 33361678
[TBL] [Abstract][Full Text] [Related]
32. [A case of neuromyelitis optica spectrum disorder after human immunodeficiency virus infection treated with rituximab].
Tada Y; Kaya H; Shima K
Rinsho Shinkeigaku; 2023 Nov; 63(11):748-753. PubMed ID: 37880114
[TBL] [Abstract][Full Text] [Related]
33. [Seroconversion of anti-aquaporin-4 antibody in a patient with neuromyelitis optica spectrum disorder: a case report].
Shimoyama K; Akahori M; Ishio Y; Yanagihara C
Rinsho Shinkeigaku; 2022 May; 62(5):351-356. PubMed ID: 35474282
[TBL] [Abstract][Full Text] [Related]
34. Neuromyelitis optica spectrum disorders: Features of aquaporin-4, myelin oligodendrocyte glycoprotein and double-seronegative-mediated subtypes.
Alves Do Rego C; Collongues N
Rev Neurol (Paris); 2018 Jun; 174(6):458-470. PubMed ID: 29685427
[TBL] [Abstract][Full Text] [Related]
35. The risk factors of neuropathic pain in neuromyelitis optica spectrum disorder: a retrospective case-cohort study.
Li X; Xu H; Zheng Z; Ouyang H; Chen G; Lou Z; Chen H; Zhang J; Zhan Y; Mao H; Zhang C; Zhao M; Zhao Y
BMC Neurol; 2022 Aug; 22(1):304. PubMed ID: 35986246
[TBL] [Abstract][Full Text] [Related]
36. [Clinical characteristics and follow-up of pediatric patients with neuromyelitis optica and neuromyelitis optica spectrum disorders].
Yun W; Weihua Z; Xiaotun R; Jiuwei L; Xinying Y; Junlan L; Changhong D; Chunhong C; Haitao R; Liying C; Fang F
Zhonghua Er Ke Za Zhi; 2015 Apr; 53(4):268-73. PubMed ID: 26182501
[TBL] [Abstract][Full Text] [Related]
37. Targeting the complement system in neuromyelitis optica spectrum disorder.
Asavapanumas N; Tradtrantip L; Verkman AS
Expert Opin Biol Ther; 2021 Aug; 21(8):1073-1086. PubMed ID: 33513036
[TBL] [Abstract][Full Text] [Related]
38. Anti-MOG associated disorder-Clinical and radiological characteristics compared to AQP4-IgG+ NMOSD-A single-center experience.
Rempe T; Tarhan B; Rodriguez E; Viswanathan VT; Gyang TV; Carlson A; Tuna IS; Rees J
Mult Scler Relat Disord; 2021 Feb; 48():102718. PubMed ID: 33388560
[TBL] [Abstract][Full Text] [Related]
39. AQP4-IgG-seropositive neuromyelitis optica spectrum disorder (NMOSD) coexisting with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis: A case report and literature review.
Tao S; Zhang Y; Ye H; Guo D
Mult Scler Relat Disord; 2019 Oct; 35():185-192. PubMed ID: 31398657
[TBL] [Abstract][Full Text] [Related]
40. Immunoadsorption plasmapheresis treatment for the recurrent exacerbation of neuromyelitis optica spectrum disorder with a fluctuating anti-aquaporin-4 antibody level.
Nishimura H; Enokida H; Sakamoto T; Takahashi T; Hayami H; Nakagawa M
J Artif Organs; 2018 Sep; 21(3):378-382. PubMed ID: 29675599
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
